

LAP6 REC'd PCT/PTO 07 JUL 2006

WO 2005/067951

PCT/EP2005/000191

1

BOTANICAL EXTRACT COMPOSITION

The present invention relates to a kit comprising six botanic
5 compositions. The invention further relates to a kit for use
as a medicament, to a kit for use in the treatment of
disorders in mammals, like humans, horses, cows, pigs and
pets, to a kit for use in the treatment of lupus, multiple
10 sclerosis, rheumatoid arthritis, rheumatism, osteoporosis,
asthma in humans or tale and mane eczema in horses, and to
the use of the kit for the treatment of lupus, multiple
sclerosis, rheumatoid arthritis, rheumatism, osteoporosis,
asthma in humans or tale and mane eczema in horses

15 Lupus and tale and mane eczema are diseases which are
characterized by a complete derangement of the metabolism in
a human or horse, respectively. Lupus is a general name for
several auto-immune diseases such as lupus erythematosus,
lupus verucosus, lupus vulgaris, psoreasis and eczema. Tale
20 and mane eczema, also known as summer-itching or sweet-
itching, is a disease that is common under horses.
It is believed that the complete derangement of the
metabolism in the human or horse results in an accumulation
of homotoxins in the connective tissues located in the skin
25 of humans or in the tale region or mane region of horses.
However, it may also manifest itself in other parts of the
body, such as internal organs.

The skin of human patients suffering from lupus is often very
sensitive to light. In severe cases direct light exposure
30 should be avoided, ultimately leading to a social isolation
of the patient. Further, it is known that patients suffering
from lupus may have a poorly working liver or kidney due to
progressive attacks of inflammation.

WO 2005/067951

PCT/EP2005/000191

2

Horses suffering from tale and mane eczema feel a constant itching in the affected places. To alleviate this itching, horses scratch their affected places on rough surfaces. However, this scratching leads to severe inflammation of the
5 affected places and ultimately the horses are no longer capable of functioning normally.

Although, lupus and tale and mane eczema are diseases which are known for many years, a truly effective cure has not yet been found. Treatments used at present focus on symptoms,
10 i.e. inflammation, but do not treat the disease itself.

The objective of the present invention is to provide for a medicament which is truly effective for use in the treatment of lupus and tale and mane eczema.
15

A first aspect of the present invention relates to a kit comprising:

- a first composition comprising leaves of Melissa Officinalis, or parts thereof;
 - 20 - a second composition comprising Eleutherococcus senticosus, or parts thereof;
 - a third composition comprising Avena sativa, or parts thereof;
 - a fourth composition comprising Ballota Nigra,
25 or parts thereof;
 - a fifth composition comprising roots of Glycyrrhiza glabra/gan cao, or parts thereof; and
 - a sixth composition comprising roots of Uncaria Tomentosa, or parts thereof.
- 30 One of the pharmaceutically active compounds in the leaves of Melissa Officinalis is rose mary acid. Further, the pharmaceutically active compounds of Eleutherococcus senticosus are believed to be present in the polyphenol-

WO 2005/067951

PCT/EP2005/000191

3

fraction. Moreover, one of the pharmaceutically active compounds in parts of *Bollota Nigra* is caffeic acid. Further, the pharmaceutically active compounds of the roots of *Glycyrrhiza glabra*/gan cao are believed to be present in the saponin-fraction and the pharmaceutically active compounds of the roots of *Uncaria Tomentosa* are believed to be present in the alkaloid-fraction.

The above mentioned kit of compositions is especially suited for the treatment of human patients suffering from lupus and horses suffering from tale and mane eczema, although other mammals may also be treated with it. By administering the compositions of the kit to patients, the system-reticulo-endothelial blockade is lifted and the biofeedback restored. This leads to an improvement of the overall physical condition of the patient. It is believed that due to the improvement of the physical condition of the patient, the homotoxins which are present in connective tissue of the body are broken down. This stops the accumulation of homotoxins in the connective tissue, resulting in a halt to the inflammation of the skin and other organs. Due to the overall improvement of the physical condition of patients, the above mentioned kit can also be beneficial for human patients suffering from other diseases than lupus, such as for example multiple sclerosis, rheumatoid arthritis, rheumatism, osteoporosis and asthma.

In a preferred embodiment of the kit,

- the first composition comprises a unit dose of 100-1000 mg of leaves of *Melissa Officinalis*, or parts thereof;
- the second composition comprises a unit dose of 100-1000 mg of *Eleutherococcus senticosus*, or parts thereof;

WO 2005/067951

PCT/EP2005/000191

4

- the third composition comprises a unit dose of 100-1000 mg of *Avena sativa*, or parts thereof;
- the fourth composition comprises a unit dose of 100-1000 mg *Ballota Nigra*, or parts thereof;
- 5 - the fifth composition comprises a unit dose of 100-1000 mg of the roots of *Glycyrrhiza glabra/gan cao*, or parts thereof;
- the sixth composition comprises a unit dose of 100-1000 mg of the roots of *Uncaria Tomentosa*, or parts
- 10 thereof.

A second aspect of the present invention relates to a kit comprising:

- a first composition comprising leaves of
- 15 *Melissa Officinalis*, or parts thereof;
- a second composition comprising *Eleutherococcus senticosus*, or parts thereof;
- a third composition comprising *Avena sativa*, or parts thereof;
- 20 - a fourth composition comprising roots of *Piper methysticum*, or parts thereof;
- a fifth composition comprising roots of *Glycyrrhiza glabra/gan cao*, or parts thereof;
- a sixth composition comprising roots of *Uncaria*
- 25 *Tomentosa*, or parts thereof.

One of the pharmaceutically active compounds in the leaves of *Melissa Officinalis* is rose mary acid. Further, the pharmaceutically active compounds of *Eleutherococcus senticosus* are believed to be present in the polyphenol-

30 fraction. Moreover, one of the most important pharmaceutically active compounds in the roots of *Piper methysticum* is most likely resine. Further, it is believed that the pharmaceutically active compounds of the roots of

WO 2005/067951

PCT/EP2005/000191

5

Glycyrrhiza glabra/gan cao are present in the saponin-fraction and that the pharmaceutically active compounds of the roots Uncaria Tomentosa are present in the alkaloid-fraction.

- 5 The above mentioned kit is especially suited for the treatment of horses, however other mammals may also be treated with it. It is believed that administering the compositions of the kit lifts the system-reticulo-endothelial blockade and restores the biofeedback. This leads to an
- 10 improvement of the overall physical condition of the horse. Due to the improvement of its physical condition, the homotoxins that cause the itching are broken down. This prevents the homo-toxins from accumulating in the connective tissue of the tale and mane region, resulting in less or no
- 15 itching.

In a preferred embodiment of the kit of the present invention;

- the first composition comprises a unit dose of 100-1000 mg leaves of Melissa Officinalis, or parts thereof;
- 20 - the second composition comprises a unit dose of 100-1000 mg of Eleutherococcus senticosus, or parts thereof;
- the third composition comprises a unit dose of 100-1000 mg of Avena sativa, or parts thereof;
- the fourth composition comprises a unit dose of
- 25 100-1000 mg roots of Piper methysticum, or parts thereof;
- the fifth composition comprises a unit dose of 100-1000 mg roots of Glycyrrhiza glabra/gan cao, or parts thereof.
- the sixth composition comprises a unit dose of
- 30 100-1000 mg roots of Uncaria Tomentosa, or parts thereof.

In a preferred embodiment of the above mentioned kits, a composition comprises a pharmaceutically acceptable carrier.

WO 2005/067951

PCT/EP2005/000191

6

Moreover, it is preferred if a composition is in the form of a capsule or tablet, although a liquid or sachet may also be used.

5

A third aspect of the present invention relates to a kit as described above for use as a medicament.

A fourth aspect of the present invention relates to a kit as described above for use in the treatment of disorders in

10 mammals, like humans, horses, cows, pigs and pets.

A fifth aspect of the present invention relates to a kit as described above for use in the treatment of lupus, multiple sclerosis, rheumatoid arthritis, rheumatism, osteoporosis, asthma in humans or tale and mane eczema in horses.

15 A last aspect of the present invention relates to the use of a kit as described above in the treatment of lupus, multiple sclerosis, rheumatoid arthritis, rheumatism, osteoporosis, asthma in humans or tale and mane eczema in horses.

20 The invention will be described by the following examples. These examples are given for illustration purposes and are not intended to limit the scope of the invention.

WO 2005/067951

PCT/EP2005/000191

7

EXAMPLES

Example 1

A Spanish female patient suffering from lupus erythematosus
5 was treated with the compositions of the kit of the present
invention. Before treatment the patient had a poor working
liver and was very sensitive to light. Exposure to light
caused several inflammatory places on the skin. During 5
months the patient was treated with the compositions of the
10 kit of the invention. She was administered:
- three times a day two capsules containing 210 mg of leaves
of *Melissa Officinalis*;
- three times a day two capsules containing 250 mg of
Eleutherococcus senticosus;
15 - three times a day two capsules containing 250 mg of *Avena*
sativa.
- three times a day one capsule containing 150 mg of an
extract of *Ballota nigra*;
- three times a day two capsules containing 250 mg parts of
20 the roots of *Glycyrrhiza glabra/gan cao*; and
- three times a day one capsule containing 350 mg parts of
roots of *Uncaria Tomentosa*.

After 6 months the patient was exposed to day-light and no
inflammation of the skin took place. Further, MRI-pictures
25 were taken from the liver and they showed that the dark
spots, indicating a poorly working liver, had disappeared.

Example 2

A group of 102 horses (98 Fjords, 2 Icelanders and 2 Half
30 lings) suffering from tale and mane eczema were treated with
the compositions of the kit of the present invention. Before
treatment the horses had several infections in the tale and

WO 2005/067951

PCT/EP2005/000191

8

mane region. During a period varying from 1 to 6 months the horses were administered:

- three times a day two capsules containing 210 mg of leaves of *Melissa Officinalis*;
- 5 - three times a day two capsules containing 250 mg of *Eleutherococcus senticosus*;
- three times a day two capsules containing 250 mg of *Avena sativa*;
- three times a day two capsules containing 300 mg parts of
- 10 the roots of *Piper methysticum*;
- three times a day two capsules containing 250 mg parts of the roots of *Glycyrrhiza glabra/gan cao*;
- three times a day one capsule containing 350 mg parts of the roots of *Uncaria Tomentosa*.
- 15 Within a period of six months the conditions of all the horses were evaluated. Seventy nine horses did no longer suffer from tale and mane eczema. Twelve horses showed improvement, although the tale and mane eczema was not cured completely. Eleven horses showed no improvement. It is
- 20 believed that the disease has affect these eleven horses beyond a biological border, making treatment fruitless.

WO 2005/067951

PCT/EP2005/000191

9

CLAIMS

1. Kit comprising:

- a first composition comprising leaves of
5 *Melissa Officinalis*, or parts thereof;
- a second composition comprising *Eleutherococcus*
senticosus, or parts thereof;
- a third composition comprising *Avena sativa*, or
parts thereof;
- 10 - a fourth composition comprising *Ballota Nigra*,
or parts thereof;
- a fifth composition comprising roots of
Glycyrrhiza glabra/gan cao, or parts thereof; and
- a sixth composition comprising roots of *Uncaria*
15 *Tomentosa*, or parts thereof.

2. Kit according to claim 1, wherein

- the first composition comprises a unit dose of
100-1000 mg of leaves of *Melissa Officinalis*, or parts
thereof;
- 20 - the second composition comprises a unit dose of
100-1000 mg of *Eleutherococcus senticosus*, or parts thereof;
- the third composition comprises a unit dose of
100-1000 mg of *Avena sativa*, or parts thereof;
- the fourth composition comprises a unit dose of
25 100-1000 mg *Ballota Nigra*, or parts thereof;
- the fifth composition comprises a unit dose of
100-1000 mg of the roots of *Glycyrrhiza glabra/gan cao*, or
parts thereof;
- the sixth composition comprises a unit dose of
30 100-1000 mg of the roots of *Uncaria Tomentosa*, or parts
thereof.

3. Kit comprising:

WO 2005/067951

PCT/EP2005/000191

10

- a first composition comprising leaves of
Melissa Officinalis, or parts thereof;
- a second composition comprising Eleutherococcus
senticosus, or parts thereof;
- 5 - a third composition comprising Avena sativa, or
parts thereof;
- a fourth composition comprising roots of Piper
methysticum, or parts thereof;
- a fifth composition comprising roots of
10 Glycyrrhiza glabra/gan cao, or parts thereof;
- a sixth composition comprising roots of Uncaria
Tomentosa, or parts thereof.
- 4. Kit according to claim 3, wherein
 - the first composition comprises a unit dose of
15 100-1000 mg leaves of Melissa Officinalis, or parts thereof;
 - the second composition comprises a unit dose of
100-1000 mg of Eleutherococcus senticosus, or parts thereof;
 - the third composition comprises a unit dose of
100-1000 mg of Avena sativa, or parts thereof;
 - 20 - the fourth composition comprises a unit dose of
100-1000 mg roots of Piper methysticum, or parts thereof;
 - the fifth composition comprises a unit dose of
100-1000 mg roots of Glycyrrhiza glabra/gan cao, or parts
thereof.
 - 25 - the sixth composition comprises a unit dose of
100-1000 mg roots of Uncaria Tomentosa, or parts thereof.
- 5. Kit according to any of the claims 1-4, wherein a
composition comprises a pharmaceutically acceptable carrier.
- 6. Kit according to claim 1-5 wherein a composition
30 is in the form of a capsule or tablet.
- 7. Kit according to claim 1-6 for use as a
medicament.

WO 2005/067951

PCT/EP2005/000191

11

8. Kit according to any of the claims 1-6 for use in the treatment of disorders in mammals, like humans, horses, cows, pigs and pets.

5 9. Kit according to any of the claims 1-6 for use in the treatment of lupus, multiple sclerosis, rheumatoid arthritis, rheumatism, osteoporosis, asthma in humans or tale and mane eczema in horses.

10 10. Use of a kit according to claim 1-6 for the treatment of lupus, multiple sclerosis, rheumatoid arthritis, rheumatism, osteoporosis, asthma in humans or tale and mane eczema in horses.